Amarin Corp has filed a patent for pharmaceutical compositions containing eicosapentaenoic acid, derivatives, and nicotinic acid for treating various diseases. Claims 1-15 have been canceled. GlobalData’s report on Amarin Corp gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Amarin Corp Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Amarin Corp, Cancer treatment biomarkers was a key innovation area identified from patents. Amarin Corp's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition for treating carious diseases and disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Amarin Corp Plc

A recently filed patent (Publication Number: US20240024269A1) discloses a composition comprising eicosapentaenoic acid (EPA) co-formulated with a statin. The composition is defined by specific criteria, including EPA making up at least 90% of all fatty acids, a limited presence of other fatty acids, and a restriction on docosahexaenoic acid (DHA) content. The patent also covers various solid dosage forms for the composition, such as tablets, capsules, powders, and aerosol formulations, with the EPA and statin potentially co-formulated in the same dosage unit.

Furthermore, the patent details a method for treating cardiovascular diseases or disorders by administering the EPA and statin composition to a subject in need. The method aligns with the composition criteria outlined in the patent, emphasizing the importance of EPA content and the limited presence of other fatty acids or DHA derivatives. The solid dosage forms mentioned for the composition are also applicable to the treatment method, with the potential for co-formulation of EPA and statin in the same dosage unit for effective administration. Specific statins like rosuvastatin are highlighted in the patent, with dosage ranges specified for optimal treatment outcomes, further solidifying the patent's focus on a novel approach to cardiovascular disease management.

To know more about GlobalData’s detailed insights on Amarin Corp, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies